| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medical Records Systems, Computerized | 48 | 2020 | 1195 | 4.310 |
Why?
|
| Electronic Health Records | 77 | 2024 | 4863 | 4.170 |
Why?
|
| Computational Biology | 44 | 2021 | 3565 | 3.610 |
Why?
|
| Genomics | 48 | 2024 | 5926 | 3.100 |
Why?
|
| Rare Diseases | 20 | 2024 | 630 | 3.020 |
Why?
|
| Information Storage and Retrieval | 30 | 2019 | 831 | 2.970 |
Why?
|
| Autistic Disorder | 14 | 2024 | 1238 | 2.520 |
Why?
|
| Software | 49 | 2021 | 4463 | 2.400 |
Why?
|
| Gene Expression Profiling | 62 | 2020 | 9527 | 2.300 |
Why?
|
| Medical Informatics | 19 | 2021 | 743 | 2.240 |
Why?
|
| Databases, Genetic | 29 | 2020 | 1756 | 2.220 |
Why?
|
| Phenotype | 68 | 2024 | 16716 | 1.930 |
Why?
|
| Computer Communication Networks | 21 | 2020 | 292 | 1.920 |
Why?
|
| Genome, Human | 30 | 2024 | 4443 | 1.810 |
Why?
|
| Confidentiality | 21 | 2019 | 607 | 1.550 |
Why?
|
| Algorithms | 58 | 2022 | 14066 | 1.550 |
Why?
|
| Developmental Disabilities | 11 | 2023 | 1519 | 1.530 |
Why?
|
| Microcephaly | 5 | 2023 | 427 | 1.530 |
Why?
|
| Artificial Intelligence | 20 | 2024 | 2662 | 1.510 |
Why?
|
| Information Dissemination | 15 | 2024 | 1142 | 1.500 |
Why?
|
| Medical Record Linkage | 12 | 2021 | 286 | 1.490 |
Why?
|
| Natural Language Processing | 21 | 2020 | 1198 | 1.470 |
Why?
|
| Systems Integration | 15 | 2017 | 425 | 1.420 |
Why?
|
| Computer Security | 18 | 2022 | 261 | 1.410 |
Why?
|
| Nervous System Malformations | 3 | 2022 | 243 | 1.400 |
Why?
|
| Humans | 495 | 2024 | 766117 | 1.350 |
Why?
|
| Child Development Disorders, Pervasive | 6 | 2013 | 597 | 1.320 |
Why?
|
| User-Computer Interface | 23 | 2020 | 1407 | 1.260 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 38 | 2012 | 3796 | 1.220 |
Why?
|
| Epilepsy | 8 | 2024 | 3317 | 1.120 |
Why?
|
| Biomedical Research | 13 | 2021 | 3458 | 1.110 |
Why?
|
| Genetic Variation | 21 | 2020 | 6612 | 1.100 |
Why?
|
| Delivery of Health Care | 12 | 2024 | 5367 | 1.090 |
Why?
|
| Sequence Analysis, DNA | 20 | 2021 | 4780 | 1.060 |
Why?
|
| Database Management Systems | 8 | 2010 | 263 | 1.060 |
Why?
|
| Inflammatory Bowel Diseases | 14 | 2019 | 2431 | 0.990 |
Why?
|
| Depressive Disorder, Major | 20 | 2021 | 4809 | 0.970 |
Why?
|
| Genetic Testing | 17 | 2024 | 3594 | 0.960 |
Why?
|
| Colitis, Ulcerative | 10 | 2023 | 1912 | 0.950 |
Why?
|
| Data Collection | 8 | 2021 | 3318 | 0.940 |
Why?
|
| Internet | 25 | 2015 | 3107 | 0.930 |
Why?
|
| Genes | 6 | 2019 | 1824 | 0.920 |
Why?
|
| Medical Informatics Applications | 6 | 2011 | 180 | 0.910 |
Why?
|
| Genetic Predisposition to Disease | 33 | 2024 | 18076 | 0.900 |
Why?
|
| Hospital Information Systems | 14 | 2009 | 395 | 0.900 |
Why?
|
| Incidental Findings | 5 | 2014 | 698 | 0.880 |
Why?
|
| Polymorphism, Single Nucleotide | 28 | 2023 | 16040 | 0.880 |
Why?
|
| Child | 81 | 2024 | 80573 | 0.850 |
Why?
|
| Patient Access to Records | 4 | 2016 | 120 | 0.830 |
Why?
|
| Gene Expression Regulation | 32 | 2019 | 11906 | 0.830 |
Why?
|
| Crohn Disease | 9 | 2019 | 2281 | 0.830 |
Why?
|
| Data Mining | 9 | 2021 | 560 | 0.810 |
Why?
|
| Golgi Apparatus | 1 | 2024 | 405 | 0.800 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2020 | 614 | 0.790 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2022 | 42 | 0.780 |
Why?
|
| Patients | 4 | 2023 | 908 | 0.780 |
Why?
|
| Nervous System Diseases | 5 | 2023 | 1657 | 0.770 |
Why?
|
| Genome-Wide Association Study | 28 | 2023 | 12803 | 0.760 |
Why?
|
| Software Design | 4 | 2012 | 173 | 0.760 |
Why?
|
| Mutation | 26 | 2024 | 30209 | 0.760 |
Why?
|
| Electron Transport Complex III | 1 | 2021 | 31 | 0.740 |
Why?
|
| Electron Transport Complex II | 1 | 2021 | 53 | 0.740 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2019 | 146 | 0.730 |
Why?
|
| National Library of Medicine (U.S.) | 2 | 2019 | 34 | 0.720 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2020 | 33 | 0.710 |
Why?
|
| Medicine | 3 | 2023 | 944 | 0.710 |
Why?
|
| Access to Information | 2 | 2022 | 317 | 0.700 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 2 | 2020 | 256 | 0.680 |
Why?
|
| Clinical Laboratory Techniques | 6 | 2018 | 746 | 0.680 |
Why?
|
| Cerebellar Ataxia | 1 | 2021 | 150 | 0.660 |
Why?
|
| Neuromuscular Diseases | 2 | 2019 | 260 | 0.660 |
Why?
|
| Spasms, Infantile | 4 | 2021 | 300 | 0.660 |
Why?
|
| Genetic Association Studies | 8 | 2021 | 2744 | 0.650 |
Why?
|
| Gene Expression Regulation, Developmental | 6 | 2020 | 3606 | 0.640 |
Why?
|
| Male | 155 | 2024 | 363935 | 0.630 |
Why?
|
| Coloboma | 1 | 2019 | 60 | 0.630 |
Why?
|
| Platinum | 1 | 2020 | 219 | 0.630 |
Why?
|
| Parents | 11 | 2023 | 3591 | 0.630 |
Why?
|
| False Positive Reactions | 7 | 2016 | 956 | 0.630 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 291 | 0.630 |
Why?
|
| Cerebellum | 7 | 2019 | 1519 | 0.630 |
Why?
|
| Female | 169 | 2024 | 396233 | 0.630 |
Why?
|
| Genome | 10 | 2021 | 1753 | 0.630 |
Why?
|
| Clinical Laboratory Information Systems | 4 | 2012 | 108 | 0.620 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 89 | 0.620 |
Why?
|
| Papilledema | 1 | 2020 | 130 | 0.620 |
Why?
|
| Arthrogryposis | 1 | 2019 | 69 | 0.610 |
Why?
|
| Fraud | 1 | 2019 | 66 | 0.610 |
Why?
|
| Models, Genetic | 20 | 2020 | 3448 | 0.600 |
Why?
|
| Zebrafish | 6 | 2024 | 3035 | 0.600 |
Why?
|
| Pharmacogenetics | 3 | 2014 | 682 | 0.600 |
Why?
|
| Gene Expression | 15 | 2017 | 7582 | 0.590 |
Why?
|
| Siblings | 4 | 2024 | 828 | 0.590 |
Why?
|
| Reproducibility of Results | 39 | 2023 | 20137 | 0.590 |
Why?
|
| Caenorhabditis elegans Proteins | 2 | 2020 | 883 | 0.590 |
Why?
|
| Information Systems | 6 | 2021 | 400 | 0.580 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2024 | 572 | 0.580 |
Why?
|
| Genotype | 16 | 2021 | 13028 | 0.570 |
Why?
|
| Databases, Factual | 21 | 2021 | 8062 | 0.570 |
Why?
|
| Mitochondrial Diseases | 1 | 2021 | 344 | 0.560 |
Why?
|
| Comorbidity | 13 | 2022 | 10579 | 0.560 |
Why?
|
| Databases as Topic | 5 | 2002 | 472 | 0.560 |
Why?
|
| Epistasis, Genetic | 1 | 2019 | 353 | 0.550 |
Why?
|
| Child, Preschool | 45 | 2024 | 42511 | 0.550 |
Why?
|
| United States | 61 | 2024 | 72920 | 0.540 |
Why?
|
| Computer Systems | 15 | 2011 | 468 | 0.540 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2022 | 1177 | 0.540 |
Why?
|
| MicroRNAs | 6 | 2022 | 3787 | 0.530 |
Why?
|
| Bayes Theorem | 9 | 2019 | 2353 | 0.530 |
Why?
|
| NF-kappa B | 2 | 2022 | 2495 | 0.520 |
Why?
|
| Multifactorial Inheritance | 9 | 2023 | 1426 | 0.520 |
Why?
|
| Medical Records | 7 | 2017 | 1408 | 0.520 |
Why?
|
| Adolescent | 53 | 2024 | 88819 | 0.510 |
Why?
|
| Patient Selection | 4 | 2021 | 4249 | 0.510 |
Why?
|
| Adult | 97 | 2024 | 223139 | 0.510 |
Why?
|
| Research Design | 7 | 2021 | 6206 | 0.500 |
Why?
|
| Caenorhabditis elegans | 3 | 2023 | 1476 | 0.500 |
Why?
|
| Programming Languages | 8 | 2017 | 133 | 0.500 |
Why?
|
| Toxicogenetics | 2 | 2016 | 19 | 0.500 |
Why?
|
| Translating | 1 | 2016 | 144 | 0.490 |
Why?
|
| Insurance Claim Review | 2 | 2021 | 744 | 0.490 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2019 | 242 | 0.490 |
Why?
|
| Lung Neoplasms | 9 | 2020 | 13483 | 0.490 |
Why?
|
| Protein Kinases | 1 | 2022 | 1611 | 0.490 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 2177 | 0.490 |
Why?
|
| Autoimmune Diseases | 5 | 2024 | 2249 | 0.490 |
Why?
|
| Dyslipidemias | 2 | 2020 | 871 | 0.480 |
Why?
|
| Evidence-Based Medicine | 4 | 2019 | 3690 | 0.480 |
Why?
|
| Genetics, Medical | 5 | 2013 | 334 | 0.480 |
Why?
|
| Cohort Studies | 42 | 2023 | 41684 | 0.470 |
Why?
|
| Haploinsufficiency | 3 | 2024 | 334 | 0.470 |
Why?
|
| Seizures | 4 | 2024 | 2997 | 0.460 |
Why?
|
| Eye Diseases | 1 | 2020 | 660 | 0.460 |
Why?
|
| Genetics, Population | 3 | 2009 | 943 | 0.460 |
Why?
|
| Benchmarking | 1 | 2021 | 1055 | 0.450 |
Why?
|
| Forecasting | 6 | 2021 | 2936 | 0.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2018 | 8612 | 0.450 |
Why?
|
| Databases, Nucleic Acid | 7 | 2005 | 203 | 0.450 |
Why?
|
| Penetrance | 1 | 2016 | 388 | 0.450 |
Why?
|
| ROC Curve | 16 | 2023 | 3614 | 0.450 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 3836 | 0.440 |
Why?
|
| Metabolomics | 3 | 2021 | 1667 | 0.440 |
Why?
|
| Syndrome | 10 | 2023 | 3270 | 0.440 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 8038 | 0.430 |
Why?
|
| Cluster Analysis | 19 | 2019 | 2718 | 0.430 |
Why?
|
| International Classification of Diseases | 8 | 2019 | 934 | 0.420 |
Why?
|
| Family | 5 | 2024 | 3208 | 0.420 |
Why?
|
| Transcription Factors | 15 | 2023 | 12130 | 0.420 |
Why?
|
| Genetic Counseling | 4 | 2021 | 634 | 0.410 |
Why?
|
| Arthritis, Rheumatoid | 12 | 2020 | 3743 | 0.410 |
Why?
|
| Young Adult | 34 | 2024 | 59868 | 0.410 |
Why?
|
| Computing Methodologies | 1 | 2012 | 17 | 0.410 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2022 | 16 | 0.400 |
Why?
|
| Lamin Type B | 1 | 2022 | 28 | 0.390 |
Why?
|
| Neuroaxonal Dystrophies | 1 | 2022 | 26 | 0.390 |
Why?
|
| Animals | 65 | 2024 | 168800 | 0.390 |
Why?
|
| Informatics | 1 | 2012 | 72 | 0.390 |
Why?
|
| Genetic Diseases, Inborn | 4 | 2019 | 606 | 0.390 |
Why?
|
| Case-Control Studies | 25 | 2024 | 22228 | 0.390 |
Why?
|
| Genetic Research | 3 | 2014 | 173 | 0.390 |
Why?
|
| Marfan Syndrome | 1 | 2024 | 237 | 0.380 |
Why?
|
| Gastrointestinal Agents | 2 | 2016 | 511 | 0.380 |
Why?
|
| Infant | 29 | 2022 | 36427 | 0.380 |
Why?
|
| Infant, Newborn | 29 | 2022 | 26381 | 0.380 |
Why?
|
| Models, Organizational | 1 | 2015 | 548 | 0.380 |
Why?
|
| Health Insurance Portability and Accountability Act | 3 | 2020 | 104 | 0.380 |
Why?
|
| Alleles | 14 | 2024 | 6892 | 0.380 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 784 | 0.380 |
Why?
|
| Medical History Taking | 5 | 2017 | 779 | 0.380 |
Why?
|
| Computer Simulation | 15 | 2023 | 6254 | 0.380 |
Why?
|
| Colon | 1 | 2019 | 1797 | 0.370 |
Why?
|
| Muscular Diseases | 2 | 2024 | 551 | 0.370 |
Why?
|
| Health Records, Personal | 3 | 2022 | 126 | 0.370 |
Why?
|
| Physician-Patient Relations | 5 | 2017 | 3270 | 0.370 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2024 | 833 | 0.370 |
Why?
|
| Bipolar Disorder | 7 | 2021 | 5128 | 0.370 |
Why?
|
| Monitoring, Physiologic | 10 | 2022 | 1794 | 0.370 |
Why?
|
| Peer Review, Research | 3 | 2021 | 342 | 0.370 |
Why?
|
| Calcium Channels, L-Type | 2 | 2024 | 243 | 0.370 |
Why?
|
| Sequence Homology | 2 | 2019 | 197 | 0.360 |
Why?
|
| Angelman Syndrome | 1 | 2023 | 139 | 0.360 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2012 | 2838 | 0.360 |
Why?
|
| Middle Aged | 76 | 2024 | 223083 | 0.360 |
Why?
|
| Patient Identification Systems | 4 | 2007 | 75 | 0.360 |
Why?
|
| Connective Tissue Diseases | 1 | 2024 | 284 | 0.360 |
Why?
|
| Conserved Sequence | 3 | 2005 | 1159 | 0.360 |
Why?
|
| Telemedicine | 3 | 2023 | 3108 | 0.360 |
Why?
|
| Toll-Like Receptors | 1 | 2024 | 582 | 0.350 |
Why?
|
| Data Interpretation, Statistical | 7 | 2019 | 2689 | 0.350 |
Why?
|
| Telomere | 1 | 2017 | 941 | 0.350 |
Why?
|
| S Phase | 2 | 2011 | 423 | 0.350 |
Why?
|
| Pandemics | 10 | 2024 | 8725 | 0.350 |
Why?
|
| Tuberous Sclerosis | 1 | 2018 | 1039 | 0.350 |
Why?
|
| Toxicity Tests | 1 | 2010 | 112 | 0.350 |
Why?
|
| Genetic Privacy | 2 | 2009 | 59 | 0.350 |
Why?
|
| Teratogens | 1 | 2010 | 120 | 0.340 |
Why?
|
| Trinucleotide Repeat Expansion | 4 | 2014 | 253 | 0.340 |
Why?
|
| Expert Systems | 3 | 1996 | 79 | 0.340 |
Why?
|
| DNA Copy Number Variations | 3 | 2014 | 2045 | 0.340 |
Why?
|
| Vaccination | 1 | 2022 | 3431 | 0.340 |
Why?
|
| Autoimmunity | 3 | 2024 | 1354 | 0.340 |
Why?
|
| Public Health | 2 | 2022 | 2681 | 0.340 |
Why?
|
| Proteome | 2 | 2018 | 1896 | 0.330 |
Why?
|
| Sequence Alignment | 7 | 2005 | 2174 | 0.330 |
Why?
|
| Hospital Shared Services | 1 | 2009 | 16 | 0.330 |
Why?
|
| Albinism | 1 | 2019 | 25 | 0.330 |
Why?
|
| Craniofacial Abnormalities | 2 | 2023 | 320 | 0.330 |
Why?
|
| Genetic Markers | 4 | 2013 | 2603 | 0.330 |
Why?
|
| Movement Disorders | 1 | 2023 | 461 | 0.330 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2001 | 618 | 0.330 |
Why?
|
| Fibroblasts | 6 | 2021 | 4162 | 0.330 |
Why?
|
| Pedigree | 5 | 2024 | 4535 | 0.330 |
Why?
|
| Spastic Paraplegia, Hereditary | 2 | 2023 | 171 | 0.320 |
Why?
|
| Depression | 6 | 2021 | 8230 | 0.320 |
Why?
|
| Retrospective Studies | 33 | 2023 | 81565 | 0.320 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 997 | 0.320 |
Why?
|
| Biotechnology | 1 | 2011 | 284 | 0.320 |
Why?
|
| Muscle, Skeletal | 14 | 2024 | 4959 | 0.310 |
Why?
|
| Geography | 2 | 2010 | 651 | 0.310 |
Why?
|
| Cooperative Behavior | 4 | 2012 | 1512 | 0.310 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2012 | 798 | 0.310 |
Why?
|
| Acids | 1 | 2019 | 125 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2020 | 5388 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 4342 | 0.310 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2019 | 80 | 0.310 |
Why?
|
| American Recovery and Reinvestment Act | 2 | 2020 | 72 | 0.310 |
Why?
|
| Chromosomes, Mammalian | 2 | 2007 | 147 | 0.300 |
Why?
|
| Membrane Transport Proteins | 1 | 2024 | 1029 | 0.300 |
Why?
|
| Schizophrenia | 7 | 2022 | 6975 | 0.300 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 3048 | 0.300 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2008 | 178 | 0.300 |
Why?
|
| Publications | 1 | 2010 | 195 | 0.300 |
Why?
|
| Eye Abnormalities | 1 | 2020 | 242 | 0.300 |
Why?
|
| Huntington Disease | 5 | 2014 | 1147 | 0.300 |
Why?
|
| Mobile Health Units | 1 | 2009 | 91 | 0.300 |
Why?
|
| Hospitalization | 14 | 2022 | 10811 | 0.300 |
Why?
|
| Suicide | 1 | 2019 | 1606 | 0.300 |
Why?
|
| Leukocytes | 2 | 2017 | 2030 | 0.300 |
Why?
|
| Chloride Channels | 1 | 2019 | 221 | 0.290 |
Why?
|
| Communication | 6 | 2020 | 3909 | 0.290 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2010 | 336 | 0.290 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2023 | 2255 | 0.290 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2018 | 82 | 0.290 |
Why?
|
| Models, Theoretical | 5 | 2017 | 3561 | 0.290 |
Why?
|
| Lipomatosis | 1 | 2018 | 112 | 0.290 |
Why?
|
| Research Personnel | 1 | 2012 | 589 | 0.290 |
Why?
|
| Heart Conduction System | 1 | 2013 | 1007 | 0.280 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 1662 | 0.280 |
Why?
|
| RNA, Messenger | 19 | 2023 | 12775 | 0.280 |
Why?
|
| Carrier Proteins | 3 | 2023 | 4910 | 0.280 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2019 | 698 | 0.280 |
Why?
|
| Time | 4 | 2001 | 549 | 0.280 |
Why?
|
| Patient Care | 1 | 2013 | 630 | 0.280 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 1768 | 0.280 |
Why?
|
| Informed Consent | 4 | 2011 | 1010 | 0.280 |
Why?
|
| Heterozygote | 6 | 2023 | 2796 | 0.280 |
Why?
|
| Classification | 1 | 2007 | 128 | 0.280 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 1338 | 0.280 |
Why?
|
| Databases, Protein | 3 | 2006 | 391 | 0.270 |
Why?
|
| Antigens, Human Platelet | 2 | 2018 | 41 | 0.270 |
Why?
|
| Ear, External | 1 | 2007 | 165 | 0.270 |
Why?
|
| Publishing | 4 | 2021 | 836 | 0.270 |
Why?
|
| Commerce | 1 | 2012 | 612 | 0.270 |
Why?
|
| Bone Marrow Diseases | 1 | 2018 | 234 | 0.270 |
Why?
|
| Micronucleus, Germline | 1 | 2006 | 6 | 0.270 |
Why?
|
| Vocabulary, Controlled | 5 | 2012 | 170 | 0.260 |
Why?
|
| Mutation, Missense | 6 | 2023 | 2590 | 0.260 |
Why?
|
| Vitamin A | 1 | 2009 | 611 | 0.260 |
Why?
|
| Trinucleotide Repeats | 3 | 2013 | 257 | 0.260 |
Why?
|
| Models, Biological | 12 | 2013 | 9445 | 0.260 |
Why?
|
| Boston | 15 | 2018 | 9335 | 0.260 |
Why?
|
| Gene Regulatory Networks | 6 | 2015 | 1750 | 0.260 |
Why?
|
| Signal Transduction | 15 | 2020 | 23605 | 0.260 |
Why?
|
| Aged | 49 | 2023 | 171219 | 0.260 |
Why?
|
| Mice | 37 | 2024 | 81839 | 0.250 |
Why?
|
| Blood Group Antigens | 2 | 2018 | 183 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2016 | 3249 | 0.250 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1536 | 0.250 |
Why?
|
| Government Regulation | 3 | 2017 | 525 | 0.250 |
Why?
|
| Diabetes Mellitus | 8 | 2015 | 5889 | 0.250 |
Why?
|
| PubMed | 2 | 2019 | 130 | 0.250 |
Why?
|
| Depressive Disorder | 5 | 2021 | 3712 | 0.250 |
Why?
|
| Pluripotent Stem Cells | 1 | 2012 | 808 | 0.250 |
Why?
|
| Decision Making | 4 | 2019 | 3955 | 0.250 |
Why?
|
| Mosaicism | 2 | 2024 | 481 | 0.250 |
Why?
|
| Cardiomyopathies | 3 | 2024 | 2068 | 0.250 |
Why?
|
| Attitude to Computers | 6 | 2012 | 196 | 0.250 |
Why?
|
| Clostridium Infections | 3 | 2021 | 563 | 0.240 |
Why?
|
| Plant Extracts | 2 | 2011 | 496 | 0.240 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 656 | 0.240 |
Why?
|
| rab GTP-Binding Proteins | 2 | 2024 | 247 | 0.240 |
Why?
|
| Risk Factors | 35 | 2021 | 74857 | 0.240 |
Why?
|
| GTP Phosphohydrolases | 1 | 2018 | 524 | 0.240 |
Why?
|
| Molecular Sequence Annotation | 4 | 2017 | 526 | 0.240 |
Why?
|
| Bibliometrics | 1 | 2009 | 356 | 0.240 |
Why?
|
| Workflow | 2 | 2021 | 859 | 0.240 |
Why?
|
| Area Under Curve | 5 | 2021 | 1638 | 0.240 |
Why?
|
| Lipids | 4 | 2024 | 3316 | 0.240 |
Why?
|
| Insurance, Health | 6 | 2021 | 2520 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 4049 | 0.240 |
Why?
|
| Drug Repositioning | 2 | 2018 | 245 | 0.230 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 4556 | 0.230 |
Why?
|
| Periodicals as Topic | 3 | 2012 | 1463 | 0.230 |
Why?
|
| Immunity, Innate | 1 | 2016 | 3079 | 0.230 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2018 | 792 | 0.230 |
Why?
|
| DNA Methylation | 3 | 2019 | 4425 | 0.230 |
Why?
|
| Drosophila Proteins | 2 | 2024 | 1704 | 0.220 |
Why?
|
| Risk Assessment | 15 | 2021 | 24276 | 0.220 |
Why?
|
| Genitalia | 2 | 2019 | 114 | 0.220 |
Why?
|
| Mitochondria | 4 | 2019 | 3672 | 0.220 |
Why?
|
| Pharmaceutical Preparations | 3 | 2020 | 1084 | 0.220 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2023 | 47 | 0.220 |
Why?
|
| Diagnostic Imaging | 4 | 2022 | 3530 | 0.220 |
Why?
|
| Altruism | 1 | 2005 | 211 | 0.220 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2014 | 82 | 0.220 |
Why?
|
| Nutrition Surveys | 4 | 2022 | 1735 | 0.220 |
Why?
|
| Schizophrenic Psychology | 2 | 2015 | 1646 | 0.220 |
Why?
|
| Lysosomes | 1 | 2019 | 932 | 0.220 |
Why?
|
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2023 | 19 | 0.220 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4904 | 0.210 |
Why?
|
| Heart Rate | 3 | 2013 | 4204 | 0.210 |
Why?
|
| Health Services Research | 2 | 2009 | 1811 | 0.210 |
Why?
|
| Hydrocortisone | 3 | 2001 | 1832 | 0.210 |
Why?
|
| APACHE | 1 | 2004 | 268 | 0.210 |
Why?
|
| Osteochondrodysplasias | 2 | 2019 | 183 | 0.210 |
Why?
|
| Chromosome Mapping | 3 | 2006 | 4617 | 0.210 |
Why?
|
| Social Values | 1 | 2024 | 224 | 0.210 |
Why?
|
| Chromosomal Instability | 2 | 2019 | 176 | 0.210 |
Why?
|
| Referral and Consultation | 3 | 2021 | 3617 | 0.210 |
Why?
|
| Muscle Proteins | 2 | 2006 | 1160 | 0.210 |
Why?
|
| Metabolic Diseases | 2 | 2021 | 686 | 0.210 |
Why?
|
| Physicians | 5 | 2018 | 4591 | 0.210 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2007 | 329 | 0.210 |
Why?
|
| Health Policy | 1 | 2015 | 2700 | 0.210 |
Why?
|
| Emergency Service, Hospital | 9 | 2023 | 7871 | 0.200 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2011 | 497 | 0.200 |
Why?
|
| Eukaryotic Cells | 1 | 2004 | 192 | 0.200 |
Why?
|
| Environmental Exposure | 2 | 2017 | 4544 | 0.200 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2007 | 539 | 0.200 |
Why?
|
| Antidepressive Agents | 5 | 2016 | 2901 | 0.200 |
Why?
|
| Colorectal Neoplasms | 4 | 2016 | 6961 | 0.200 |
Why?
|
| Muscle Hypotonia | 3 | 2023 | 166 | 0.200 |
Why?
|
| Proteinuria | 1 | 2005 | 606 | 0.200 |
Why?
|
| Phosphatidylinositols | 1 | 2023 | 276 | 0.200 |
Why?
|
| Logistic Models | 13 | 2017 | 13273 | 0.200 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2007 | 632 | 0.200 |
Why?
|
| Serum Amyloid A Protein | 1 | 2022 | 127 | 0.200 |
Why?
|
| Models, Statistical | 8 | 2019 | 5089 | 0.200 |
Why?
|
| Privacy | 5 | 2022 | 232 | 0.200 |
Why?
|
| RNA, Neoplasm | 5 | 2006 | 745 | 0.200 |
Why?
|
| Insurance | 2 | 2021 | 115 | 0.200 |
Why?
|
| Mental Disorders | 7 | 2021 | 6871 | 0.190 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2001 | 362 | 0.190 |
Why?
|
| Public Health Practice | 2 | 2021 | 219 | 0.190 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1884 | 0.190 |
Why?
|
| Public Health Administration | 2 | 2002 | 242 | 0.190 |
Why?
|
| X Chromosome | 1 | 2005 | 819 | 0.190 |
Why?
|
| Multigene Family | 4 | 2006 | 1081 | 0.190 |
Why?
|
| Ikaros Transcription Factor | 1 | 2023 | 230 | 0.190 |
Why?
|
| Endocannabinoids | 1 | 2022 | 114 | 0.190 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2015 | 183 | 0.190 |
Why?
|
| Health Level Seven | 3 | 2016 | 35 | 0.190 |
Why?
|
| Sex Factors | 5 | 2019 | 10614 | 0.190 |
Why?
|
| DNA-Binding Proteins | 5 | 2023 | 9601 | 0.190 |
Why?
|
| Nephrotic Syndrome | 1 | 2005 | 380 | 0.190 |
Why?
|
| History, 21st Century | 3 | 2019 | 1574 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 2425 | 0.190 |
Why?
|
| Peptides | 4 | 2018 | 4338 | 0.190 |
Why?
|
| Statistics as Topic | 4 | 2014 | 2351 | 0.190 |
Why?
|
| Bioterrorism | 1 | 2002 | 144 | 0.180 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2021 | 844 | 0.180 |
Why?
|
| Infant, Premature | 4 | 2020 | 2121 | 0.180 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2021 | 85 | 0.180 |
Why?
|
| Transcription, Genetic | 12 | 2012 | 7600 | 0.180 |
Why?
|
| Sleep | 1 | 2017 | 4816 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 6 | 2017 | 4399 | 0.180 |
Why?
|
| Apraxias | 1 | 2021 | 58 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2022 | 2646 | 0.180 |
Why?
|
| Syndactyly | 1 | 2021 | 75 | 0.180 |
Why?
|
| Neoplasms | 13 | 2019 | 22344 | 0.180 |
Why?
|
| Ethers | 1 | 2020 | 72 | 0.180 |
Why?
|
| Aging | 3 | 2017 | 8723 | 0.180 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2020 | 88 | 0.180 |
Why?
|
| Population Surveillance | 5 | 2014 | 2596 | 0.180 |
Why?
|
| DNA Probes | 4 | 2005 | 541 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2008 | 2946 | 0.180 |
Why?
|
| Multivariate Analysis | 11 | 2021 | 12061 | 0.180 |
Why?
|
| Ribonuclease III | 1 | 2022 | 271 | 0.170 |
Why?
|
| Vitamin D | 4 | 2015 | 3272 | 0.170 |
Why?
|
| Growth Differentiation Factors | 1 | 2021 | 99 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 3 | 2015 | 367 | 0.170 |
Why?
|
| Search Engine | 2 | 2018 | 142 | 0.170 |
Why?
|
| Psychotic Disorders | 3 | 2022 | 3274 | 0.170 |
Why?
|
| Drosophila melanogaster | 4 | 2021 | 1725 | 0.170 |
Why?
|
| Research | 6 | 2023 | 1975 | 0.170 |
Why?
|
| Creatinine | 3 | 2022 | 1916 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 2039 | 0.170 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 2332 | 0.170 |
Why?
|
| Prognosis | 15 | 2021 | 29912 | 0.170 |
Why?
|
| Research Subjects | 2 | 2012 | 248 | 0.170 |
Why?
|
| Medical Informatics Computing | 1 | 2019 | 23 | 0.170 |
Why?
|
| Systems Biology | 3 | 2008 | 481 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2022 | 1910 | 0.170 |
Why?
|
| Growth Disorders | 2 | 1996 | 633 | 0.170 |
Why?
|
| Cell Differentiation | 3 | 2013 | 11642 | 0.170 |
Why?
|
| Up-Regulation | 7 | 2013 | 4133 | 0.170 |
Why?
|
| History, 20th Century | 2 | 2019 | 2762 | 0.170 |
Why?
|
| Risk | 9 | 2024 | 9599 | 0.170 |
Why?
|
| Hospital Communication Systems | 1 | 2000 | 47 | 0.170 |
Why?
|
| Saccharomyces cerevisiae | 8 | 2022 | 2677 | 0.160 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 2224 | 0.160 |
Why?
|
| Molecular Structure | 3 | 2021 | 1881 | 0.160 |
Why?
|
| Quality Improvement | 2 | 2018 | 3849 | 0.160 |
Why?
|
| Microarray Analysis | 3 | 2012 | 752 | 0.160 |
Why?
|
| Hypothyroidism | 2 | 2013 | 665 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2020 | 146 | 0.160 |
Why?
|
| Asthma | 8 | 2011 | 6268 | 0.160 |
Why?
|
| Methyltransferases | 1 | 2022 | 373 | 0.160 |
Why?
|
| Epigenomics | 2 | 2017 | 959 | 0.160 |
Why?
|
| Pregnancy, Multiple | 1 | 2020 | 216 | 0.160 |
Why?
|
| Laboratories, Hospital | 1 | 2000 | 192 | 0.160 |
Why?
|
| Colonoscopy | 2 | 2019 | 1408 | 0.160 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 373 | 0.160 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2019 | 62 | 0.160 |
Why?
|
| Therapy, Computer-Assisted | 3 | 1997 | 265 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2019 | 15808 | 0.160 |
Why?
|
| Child Abuse, Sexual | 1 | 2001 | 398 | 0.160 |
Why?
|
| Odds Ratio | 7 | 2022 | 9657 | 0.150 |
Why?
|
| Tissue Banks | 3 | 2012 | 183 | 0.150 |
Why?
|
| Child Abuse | 1 | 2017 | 1090 | 0.150 |
Why?
|
| Cells, Cultured | 9 | 2021 | 18967 | 0.150 |
Why?
|
| Fragile X Syndrome | 1 | 2020 | 116 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2018 | 1656 | 0.150 |
Why?
|
| Biopsy | 5 | 2019 | 6768 | 0.150 |
Why?
|
| Apoptosis | 4 | 2011 | 9508 | 0.150 |
Why?
|
| Semantics | 2 | 2019 | 609 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2000 | 715 | 0.150 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 1674 | 0.150 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2018 | 64 | 0.150 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2019 | 101 | 0.150 |
Why?
|
| Rett Syndrome | 1 | 2019 | 163 | 0.150 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2018 | 54 | 0.150 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2018 | 99 | 0.150 |
Why?
|
| Hyperbilirubinemia | 1 | 1998 | 74 | 0.150 |
Why?
|
| Insulin Resistance | 2 | 2009 | 3988 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 5 | 2011 | 5784 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 2531 | 0.140 |
Why?
|
| Computer Literacy | 1 | 1997 | 44 | 0.140 |
Why?
|
| Voice | 1 | 2001 | 268 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 2306 | 0.140 |
Why?
|
| Disease Outbreaks | 4 | 2020 | 1761 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 452 | 0.140 |
Why?
|
| Mifepristone | 1 | 2018 | 151 | 0.140 |
Why?
|
| Remote Consultation | 1 | 2000 | 241 | 0.140 |
Why?
|
| Laboratories | 2 | 2022 | 463 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2002 | 619 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2005 | 2136 | 0.140 |
Why?
|
| Trazodone | 1 | 2017 | 67 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20700 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 3107 | 0.140 |
Why?
|
| Suicide, Attempted | 2 | 2023 | 1413 | 0.140 |
Why?
|
| Neurons | 4 | 2013 | 9521 | 0.140 |
Why?
|
| Leukoencephalopathies | 1 | 2020 | 259 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2007 | 2694 | 0.140 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2020 | 354 | 0.140 |
Why?
|
| Muscular Dystrophy, Duchenne | 3 | 2005 | 271 | 0.140 |
Why?
|
| Self Report | 2 | 2020 | 3769 | 0.140 |
Why?
|
| Long QT Syndrome | 1 | 2021 | 474 | 0.130 |
Why?
|
| Unified Medical Language System | 3 | 2019 | 88 | 0.130 |
Why?
|
| Hearing | 1 | 2020 | 505 | 0.130 |
Why?
|
| Premature Birth | 2 | 2020 | 1830 | 0.130 |
Why?
|
| Prevalence | 7 | 2022 | 15827 | 0.130 |
Why?
|
| Proportional Hazards Models | 6 | 2022 | 12529 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 5 | 2008 | 6102 | 0.130 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2000 | 475 | 0.130 |
Why?
|
| Glioblastoma | 2 | 2008 | 3458 | 0.130 |
Why?
|
| Fathers | 1 | 2019 | 377 | 0.130 |
Why?
|
| Hyperlipidemias | 2 | 2018 | 770 | 0.130 |
Why?
|
| Decision Support Techniques | 4 | 2014 | 2006 | 0.130 |
Why?
|
| CpG Islands | 3 | 2011 | 1207 | 0.130 |
Why?
|
| Hyperandrogenism | 1 | 1996 | 46 | 0.130 |
Why?
|
| Probability | 6 | 2019 | 2475 | 0.130 |
Why?
|
| Hearing Loss | 1 | 2023 | 785 | 0.130 |
Why?
|
| Patient Discharge | 2 | 2015 | 3465 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2024 | 3665 | 0.130 |
Why?
|
| Social Control, Formal | 1 | 2016 | 107 | 0.130 |
Why?
|
| Weight Gain | 2 | 2017 | 2356 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1996 | 0.130 |
Why?
|
| Subcutaneous Fat | 1 | 2019 | 401 | 0.130 |
Why?
|
| Quality Control | 1 | 2018 | 835 | 0.130 |
Why?
|
| Povidone-Iodine | 1 | 1995 | 55 | 0.130 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2019 | 260 | 0.120 |
Why?
|
| Progestins | 1 | 2017 | 300 | 0.120 |
Why?
|
| Skin Care | 1 | 1995 | 54 | 0.120 |
Why?
|
| ABO Blood-Group System | 1 | 2018 | 381 | 0.120 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2022 | 1836 | 0.120 |
Why?
|
| Cell Proliferation | 6 | 2015 | 10433 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 2 | 2022 | 2232 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2011 | 1060 | 0.120 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2021 | 454 | 0.120 |
Why?
|
| Eye | 1 | 2019 | 710 | 0.120 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 3853 | 0.120 |
Why?
|
| Information Services | 3 | 2017 | 240 | 0.120 |
Why?
|
| Intensive Care Units | 4 | 2004 | 3798 | 0.120 |
Why?
|
| TYK2 Kinase | 1 | 2015 | 38 | 0.120 |
Why?
|
| Species Specificity | 5 | 2006 | 2406 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2022 | 12235 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 2327 | 0.120 |
Why?
|
| Cadherins | 1 | 2019 | 900 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 2 | 1999 | 553 | 0.120 |
Why?
|
| Patient-Centered Care | 2 | 2016 | 1447 | 0.120 |
Why?
|
| Autoantibodies | 3 | 2013 | 2114 | 0.120 |
Why?
|
| Drosophila | 4 | 2024 | 1506 | 0.120 |
Why?
|
| Epidemiologic Studies | 2 | 2015 | 677 | 0.120 |
Why?
|
| Models, Molecular | 2 | 2019 | 5382 | 0.120 |
Why?
|
| Forms and Records Control | 2 | 2008 | 158 | 0.120 |
Why?
|
| Embryonic Stem Cells | 2 | 2012 | 1242 | 0.120 |
Why?
|
| Corpus Callosum | 1 | 2019 | 751 | 0.120 |
Why?
|
| Cell Cycle | 5 | 2011 | 2920 | 0.120 |
Why?
|
| Primary Health Care | 3 | 2017 | 4736 | 0.120 |
Why?
|
| Protein Transport | 1 | 2020 | 1939 | 0.120 |
Why?
|
| Amyloidosis | 1 | 2022 | 883 | 0.120 |
Why?
|
| Puberty, Precocious | 1 | 1996 | 165 | 0.120 |
Why?
|
| Hemochromatosis | 1 | 2016 | 175 | 0.120 |
Why?
|
| Wounds and Injuries | 2 | 2019 | 2513 | 0.120 |
Why?
|
| Protein Subunits | 1 | 2018 | 940 | 0.120 |
Why?
|
| Aftercare | 1 | 2000 | 915 | 0.110 |
Why?
|
| United States Food and Drug Administration | 3 | 2019 | 1673 | 0.110 |
Why?
|
| Health Planning Guidelines | 1 | 2015 | 151 | 0.110 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2021 | 836 | 0.110 |
Why?
|
| Sequence Analysis | 1 | 2015 | 240 | 0.110 |
Why?
|
| Incidence | 9 | 2021 | 21513 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2020 | 1743 | 0.110 |
Why?
|
| Neuroma, Acoustic | 1 | 2018 | 456 | 0.110 |
Why?
|
| Point-of-Care Systems | 3 | 2016 | 1218 | 0.110 |
Why?
|
| Selection Bias | 1 | 2016 | 359 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 2824 | 0.110 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 1130 | 0.110 |
Why?
|
| Least-Squares Analysis | 3 | 2021 | 368 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2023 | 1552 | 0.110 |
Why?
|
| Vitamin D Deficiency | 2 | 2013 | 1348 | 0.110 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 1999 | 702 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 938 | 0.110 |
Why?
|
| Mass Screening | 1 | 2009 | 5450 | 0.110 |
Why?
|
| Genetic Pleiotropy | 1 | 2015 | 182 | 0.110 |
Why?
|
| Myocarditis | 1 | 2021 | 803 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 8 | 2024 | 22341 | 0.110 |
Why?
|
| Biological Products | 1 | 2023 | 947 | 0.110 |
Why?
|
| Amino Acid Transport System ASC | 1 | 2023 | 16 | 0.110 |
Why?
|
| Geographic Information Systems | 2 | 2006 | 281 | 0.110 |
Why?
|
| Biological Specimen Banks | 2 | 2020 | 787 | 0.110 |
Why?
|
| Sensitivity and Specificity | 12 | 2021 | 14645 | 0.110 |
Why?
|
| Anonymous Testing | 1 | 2013 | 10 | 0.110 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2015 | 325 | 0.110 |
Why?
|
| Counseling | 1 | 2021 | 1553 | 0.110 |
Why?
|
| Hearing Disorders | 1 | 2013 | 126 | 0.110 |
Why?
|
| DNA Damage | 2 | 2019 | 2463 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2024 | 7850 | 0.110 |
Why?
|
| Anti-Infective Agents, Local | 1 | 1995 | 246 | 0.110 |
Why?
|
| Genetic Linkage | 2 | 2012 | 2342 | 0.110 |
Why?
|
| Immunologic Factors | 3 | 2023 | 1592 | 0.110 |
Why?
|
| Predictive Value of Tests | 9 | 2014 | 15403 | 0.110 |
Why?
|
| Myopathies, Nemaline | 2 | 2004 | 73 | 0.110 |
Why?
|
| Data Display | 1 | 1994 | 174 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 15882 | 0.110 |
Why?
|
| DNA | 3 | 2019 | 7193 | 0.110 |
Why?
|
| Menarche | 1 | 1996 | 532 | 0.110 |
Why?
|
| Gait | 2 | 2023 | 819 | 0.100 |
Why?
|
| Cell Line | 9 | 2020 | 15546 | 0.100 |
Why?
|
| Parkinson Disease | 2 | 2021 | 2885 | 0.100 |
Why?
|
| Acoustic Stimulation | 1 | 2017 | 1253 | 0.100 |
Why?
|
| Names | 1 | 2013 | 54 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 3692 | 0.100 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2024 | 169 | 0.100 |
Why?
|
| Actinin | 1 | 2024 | 165 | 0.100 |
Why?
|
| Feasibility Studies | 4 | 2019 | 5300 | 0.100 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 234 | 0.100 |
Why?
|
| Hospitals, Pediatric | 7 | 2002 | 1850 | 0.100 |
Why?
|
| Amino Acid Sequence | 3 | 2019 | 13400 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 1331 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2021 | 789 | 0.100 |
Why?
|
| Brain | 6 | 2024 | 27177 | 0.100 |
Why?
|
| RNA, Ribosomal | 1 | 2013 | 227 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 2 | 2019 | 1996 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2016 | 2538 | 0.100 |
Why?
|
| DNA, Complementary | 3 | 2005 | 1984 | 0.100 |
Why?
|
| Prospective Studies | 9 | 2021 | 54812 | 0.100 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 931 | 0.100 |
Why?
|
| Principal Component Analysis | 4 | 2009 | 947 | 0.100 |
Why?
|
| Heart Arrest, Induced | 2 | 2004 | 359 | 0.100 |
Why?
|
| Hypoglycemia | 1 | 2000 | 896 | 0.100 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 310 | 0.100 |
Why?
|
| Brain Stem | 1 | 2017 | 852 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2014 | 427 | 0.100 |
Why?
|
| Medulloblastoma | 2 | 2015 | 657 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2021 | 3719 | 0.100 |
Why?
|
| Cell Lineage | 2 | 2020 | 2573 | 0.100 |
Why?
|
| Down-Regulation | 4 | 2013 | 2927 | 0.100 |
Why?
|
| RNA | 5 | 2019 | 2716 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 5510 | 0.100 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2014 | 179 | 0.100 |
Why?
|
| Chromosomes, Human, Y | 1 | 2013 | 163 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4352 | 0.100 |
Why?
|
| Human Genome Project | 2 | 2018 | 202 | 0.100 |
Why?
|
| Sex Ratio | 1 | 2012 | 107 | 0.100 |
Why?
|
| Early Diagnosis | 3 | 2016 | 1186 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2021 | 8924 | 0.100 |
Why?
|
| Sequence Inversion | 1 | 2021 | 5 | 0.100 |
Why?
|
| Base Sequence | 7 | 2022 | 12405 | 0.090 |
Why?
|
| Pregnancy | 11 | 2021 | 30233 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2017 | 6020 | 0.090 |
Why?
|
| Research Report | 1 | 2015 | 367 | 0.090 |
Why?
|
| Myocardial Infarction | 2 | 2009 | 11509 | 0.090 |
Why?
|
| Drug Utilization | 1 | 2017 | 1187 | 0.090 |
Why?
|
| Epidemiologic Research Design | 1 | 2015 | 368 | 0.090 |
Why?
|
| Ataxia | 2 | 2020 | 307 | 0.090 |
Why?
|
| Axons | 1 | 2019 | 1677 | 0.090 |
Why?
|
| Antibodies, Antinuclear | 1 | 2013 | 340 | 0.090 |
Why?
|
| Anxiety Disorders | 2 | 2013 | 2741 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 1997 | 903 | 0.090 |
Why?
|
| Eligibility Determination | 1 | 2015 | 422 | 0.090 |
Why?
|
| Health Expenditures | 2 | 2021 | 2389 | 0.090 |
Why?
|
| Curriculum | 4 | 2019 | 3784 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2019 | 3946 | 0.090 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2024 | 479 | 0.090 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2014 | 490 | 0.090 |
Why?
|
| Terpenes | 1 | 2011 | 102 | 0.090 |
Why?
|
| Oxygen | 4 | 2019 | 4247 | 0.090 |
Why?
|
| Pattern Recognition, Automated | 2 | 2008 | 979 | 0.090 |
Why?
|
| Reaction Time | 1 | 2017 | 2086 | 0.090 |
Why?
|
| RNA Editing | 1 | 2012 | 149 | 0.090 |
Why?
|
| Truth Disclosure | 2 | 2012 | 433 | 0.090 |
Why?
|
| Sjogren's Syndrome | 1 | 2013 | 240 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2020 | 1294 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 500 | 0.090 |
Why?
|
| Uncertainty | 1 | 2016 | 763 | 0.090 |
Why?
|
| RNA Splice Sites | 1 | 2022 | 212 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2007 | 1097 | 0.090 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2019 | 941 | 0.090 |
Why?
|
| Smoking | 1 | 2007 | 9082 | 0.090 |
Why?
|
| Cataract | 1 | 2017 | 837 | 0.090 |
Why?
|
| Universities | 2 | 2019 | 1004 | 0.090 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 39243 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2024 | 2879 | 0.090 |
Why?
|
| Family Relations | 1 | 2023 | 318 | 0.090 |
Why?
|
| Regression Analysis | 5 | 2021 | 6324 | 0.090 |
Why?
|
| Diabetes Complications | 2 | 2009 | 1318 | 0.090 |
Why?
|
| Parturition | 1 | 2014 | 453 | 0.090 |
Why?
|
| Paroxetine | 1 | 2011 | 181 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2009 | 4565 | 0.090 |
Why?
|
| Electronics | 2 | 2009 | 314 | 0.090 |
Why?
|
| International Cooperation | 2 | 2017 | 1433 | 0.090 |
Why?
|
| Technology | 1 | 2012 | 296 | 0.090 |
Why?
|
| Linear Models | 3 | 2017 | 5873 | 0.090 |
Why?
|
| Health Occupations | 1 | 2012 | 226 | 0.090 |
Why?
|
| New England | 4 | 2014 | 1059 | 0.090 |
Why?
|
| Time Factors | 11 | 2019 | 40108 | 0.090 |
Why?
|
| Neostriatum | 1 | 2011 | 231 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2008 | 254 | 0.090 |
Why?
|
| Cerebellar Neoplasms | 1 | 2015 | 571 | 0.090 |
Why?
|
| Metagenomics | 1 | 2014 | 473 | 0.080 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 642 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 9065 | 0.080 |
Why?
|
| Genes, Fungal | 2 | 2001 | 441 | 0.080 |
Why?
|
| Germ Cells | 1 | 2024 | 646 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4853 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2024 | 4263 | 0.080 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2018 | 2415 | 0.080 |
Why?
|
| Ethics, Medical | 2 | 2012 | 785 | 0.080 |
Why?
|
| Adenosine Triphosphatases | 1 | 2024 | 839 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2004 | 5340 | 0.080 |
Why?
|
| Limbic System | 1 | 2012 | 418 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2008 | 3751 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2022 | 10087 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2011 | 326 | 0.080 |
Why?
|
| Neurofibromin 1 | 2 | 2008 | 190 | 0.080 |
Why?
|
| Respiration, Artificial | 3 | 1997 | 2727 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 3230 | 0.080 |
Why?
|
| Public Health Informatics | 2 | 2007 | 109 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2021 | 2041 | 0.080 |
Why?
|
| Expressed Sequence Tags | 4 | 2003 | 251 | 0.080 |
Why?
|
| Drug Costs | 1 | 2017 | 1195 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2022 | 2010 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 2184 | 0.080 |
Why?
|
| Serine | 1 | 2023 | 828 | 0.080 |
Why?
|
| Pravastatin | 1 | 2011 | 391 | 0.080 |
Why?
|
| Qualitative Research | 2 | 2023 | 3138 | 0.080 |
Why?
|
| Israel | 2 | 2021 | 729 | 0.080 |
Why?
|
| Diarylheptanoids | 1 | 2008 | 2 | 0.080 |
Why?
|
| Professional-Family Relations | 1 | 2023 | 500 | 0.080 |
Why?
|
| Blood | 1 | 2011 | 597 | 0.080 |
Why?
|
| Ribonucleoprotein, U5 Small Nuclear | 1 | 2018 | 7 | 0.080 |
Why?
|
| Codon | 1 | 2011 | 599 | 0.080 |
Why?
|
| Polymorphism, Genetic | 3 | 2019 | 4249 | 0.080 |
Why?
|
| Italy | 1 | 2011 | 851 | 0.080 |
Why?
|
| Lipoproteins | 1 | 2013 | 870 | 0.080 |
Why?
|
| Ethics, Research | 1 | 2010 | 178 | 0.080 |
Why?
|
| Peptide Elongation Factors | 1 | 2018 | 59 | 0.080 |
Why?
|
| Rats | 6 | 2009 | 23717 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2008 | 614 | 0.080 |
Why?
|
| Decision Trees | 2 | 2001 | 509 | 0.080 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 1102 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2024 | 4112 | 0.080 |
Why?
|
| Pathology, Surgical | 2 | 2007 | 146 | 0.080 |
Why?
|
| Europe | 2 | 2020 | 3430 | 0.080 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 541 | 0.080 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 480 | 0.080 |
Why?
|
| Lung | 6 | 2009 | 10063 | 0.080 |
Why?
|
| Garcinia | 1 | 2008 | 3 | 0.080 |
Why?
|
| Autophagy | 1 | 2016 | 1349 | 0.080 |
Why?
|
| Medicare Part C | 1 | 2013 | 335 | 0.080 |
Why?
|
| Evolution, Molecular | 5 | 2019 | 1889 | 0.080 |
Why?
|
| Radio | 1 | 2007 | 9 | 0.070 |
Why?
|
| Globins | 1 | 2009 | 406 | 0.070 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2008 | 61 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2012 | 697 | 0.070 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 26290 | 0.070 |
Why?
|
| Intelligence | 1 | 2013 | 922 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 858 | 0.070 |
Why?
|
| Domestic Violence | 1 | 2009 | 180 | 0.070 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 161 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2004 | 7424 | 0.070 |
Why?
|
| Electronics, Medical | 1 | 2007 | 70 | 0.070 |
Why?
|
| DNA Modification Methylases | 1 | 2008 | 207 | 0.070 |
Why?
|
| Stress, Mechanical | 3 | 2007 | 1670 | 0.070 |
Why?
|
| Actins | 3 | 2023 | 2061 | 0.070 |
Why?
|
| Methods | 2 | 1998 | 1061 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2014 | 1001 | 0.070 |
Why?
|
| Circadian Rhythm | 1 | 1999 | 2594 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 544 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 11200 | 0.070 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 948 | 0.070 |
Why?
|
| Genes, Developmental | 1 | 2007 | 38 | 0.070 |
Why?
|
| Quality of Life | 3 | 2022 | 13468 | 0.070 |
Why?
|
| Patient Readmission | 3 | 2015 | 3283 | 0.070 |
Why?
|
| Receptor, EphA2 | 1 | 2006 | 41 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 373 | 0.070 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 2195 | 0.070 |
Why?
|
| Focus Groups | 1 | 2023 | 1459 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 282 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2008 | 342 | 0.070 |
Why?
|
| Nuclear Proteins | 3 | 2011 | 5791 | 0.070 |
Why?
|
| Accidental Falls | 1 | 2014 | 1079 | 0.070 |
Why?
|
| Inpatients | 1 | 2018 | 2566 | 0.070 |
Why?
|
| Bupropion | 2 | 2021 | 303 | 0.070 |
Why?
|
| DNA Repair | 3 | 2017 | 2048 | 0.070 |
Why?
|
| Myoblasts, Skeletal | 1 | 2006 | 74 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 1742 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 1651 | 0.070 |
Why?
|
| Medicare | 2 | 2022 | 6820 | 0.070 |
Why?
|
| Goals | 1 | 2011 | 717 | 0.070 |
Why?
|
| Vesicular Transport Proteins | 1 | 2009 | 376 | 0.070 |
Why?
|
| Nigeria | 1 | 2009 | 782 | 0.070 |
Why?
|
| Government Programs | 1 | 2018 | 278 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2007 | 1886 | 0.070 |
Why?
|
| Fibrinolysin | 1 | 2006 | 129 | 0.070 |
Why?
|
| Mutant Proteins | 2 | 2022 | 487 | 0.060 |
Why?
|
| Plasminogen | 1 | 2006 | 144 | 0.060 |
Why?
|
| Pediatrics | 3 | 2000 | 3609 | 0.060 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2006 | 552 | 0.060 |
Why?
|
| Animals, Congenic | 1 | 2005 | 27 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2007 | 302 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2017 | 2974 | 0.060 |
Why?
|
| Abnormalities, Multiple | 2 | 2018 | 1424 | 0.060 |
Why?
|
| Rats, Inbred Dahl | 1 | 2005 | 34 | 0.060 |
Why?
|
| Proteins | 3 | 2021 | 5995 | 0.060 |
Why?
|
| Radiology | 1 | 2019 | 2105 | 0.060 |
Why?
|
| Phylogeny | 3 | 2008 | 2838 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 3186 | 0.060 |
Why?
|
| Ethics Committees, Research | 1 | 2007 | 196 | 0.060 |
Why?
|
| Speech Disorders | 1 | 2016 | 178 | 0.060 |
Why?
|
| Regional Medical Programs | 1 | 2006 | 64 | 0.060 |
Why?
|
| Gene Knockout Techniques | 1 | 2008 | 800 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 361 | 0.060 |
Why?
|
| Rats, Inbred BN | 1 | 2005 | 229 | 0.060 |
Why?
|
| Hepatocytes | 2 | 2009 | 1246 | 0.060 |
Why?
|
| Point Mutation | 1 | 2011 | 1591 | 0.060 |
Why?
|
| Cesarean Section | 1 | 2014 | 1418 | 0.060 |
Why?
|
| Umbilical Cord | 1 | 2007 | 178 | 0.060 |
Why?
|
| Financing, Government | 1 | 2009 | 473 | 0.060 |
Why?
|
| Massachusetts | 4 | 2014 | 8882 | 0.060 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 59515 | 0.060 |
Why?
|
| Cell Line, Tumor | 9 | 2018 | 17071 | 0.060 |
Why?
|
| Kidney | 1 | 2021 | 7072 | 0.060 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2006 | 117 | 0.060 |
Why?
|
| Queensland | 1 | 2015 | 53 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 2782 | 0.060 |
Why?
|
| Haplotypes | 2 | 2019 | 2726 | 0.060 |
Why?
|
| Muscular Dystrophies | 1 | 2007 | 392 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 1204 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1559 | 0.060 |
Why?
|
| Xenopus laevis | 1 | 2019 | 965 | 0.060 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2006 | 147 | 0.060 |
Why?
|
| Lactones | 1 | 2007 | 316 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2024 | 457 | 0.060 |
Why?
|
| Pyridines | 1 | 2017 | 2889 | 0.060 |
Why?
|
| Heart Defects, Congenital | 2 | 2019 | 4712 | 0.060 |
Why?
|
| Narration | 1 | 2007 | 223 | 0.060 |
Why?
|
| Sulfones | 1 | 2007 | 447 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3594 | 0.060 |
Why?
|
| Multimedia | 1 | 2005 | 76 | 0.060 |
Why?
|
| Caspases | 1 | 2008 | 881 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2015 | 1941 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 615 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1878 | 0.060 |
Why?
|
| Mitochondria, Muscle | 1 | 2005 | 170 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 998 | 0.060 |
Why?
|
| Zinc Fingers | 1 | 2016 | 575 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 2476 | 0.060 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 1038 | 0.060 |
Why?
|
| Dystrophin | 1 | 2005 | 283 | 0.060 |
Why?
|
| Energy Metabolism | 3 | 2019 | 2894 | 0.060 |
Why?
|
| Artifacts | 4 | 2001 | 1896 | 0.060 |
Why?
|
| Oocytes | 1 | 2019 | 1168 | 0.060 |
Why?
|
| Causality | 2 | 2024 | 1247 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 1077 | 0.060 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 752 | 0.060 |
Why?
|
| Obesity | 4 | 2023 | 13085 | 0.060 |
Why?
|
| Proteomics | 1 | 2018 | 3907 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 4282 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2008 | 1213 | 0.060 |
Why?
|
| Mortality | 1 | 2015 | 2911 | 0.060 |
Why?
|
| Fetal Development | 1 | 2009 | 777 | 0.060 |
Why?
|
| Ribosomal Proteins | 1 | 2006 | 368 | 0.060 |
Why?
|
| Diagnosis | 1 | 2005 | 157 | 0.060 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2023 | 17 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2009 | 727 | 0.060 |
Why?
|
| Gene Order | 1 | 2004 | 164 | 0.050 |
Why?
|
| RNA, Complementary | 1 | 2003 | 46 | 0.050 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2017 | 300 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 2 | 2023 | 1610 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2009 | 961 | 0.050 |
Why?
|
| Statistical Distributions | 1 | 2003 | 60 | 0.050 |
Why?
|
| RNA Probes | 1 | 2003 | 110 | 0.050 |
Why?
|
| Myocardium | 3 | 2006 | 4766 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2021 | 2667 | 0.050 |
Why?
|
| Inflammation | 2 | 2022 | 10860 | 0.050 |
Why?
|
| Emotions | 1 | 2015 | 2758 | 0.050 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2009 | 789 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2023 | 69 | 0.050 |
Why?
|
| Telepathology | 1 | 2004 | 77 | 0.050 |
Why?
|
| Myositis | 2 | 2005 | 271 | 0.050 |
Why?
|
| Maternal Exposure | 1 | 2010 | 1098 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 2019 | 0.050 |
Why?
|
| Pathology, Clinical | 1 | 2007 | 374 | 0.050 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2023 | 41 | 0.050 |
Why?
|
| Office Visits | 1 | 2007 | 594 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2019 | 1127 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2008 | 5020 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2015 | 447 | 0.050 |
Why?
|
| Registries | 3 | 2021 | 8347 | 0.050 |
Why?
|
| Alternative Splicing | 2 | 2023 | 1103 | 0.050 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2023 | 201 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 2271 | 0.050 |
Why?
|
| Patient Participation | 2 | 2010 | 1447 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3111 | 0.050 |
Why?
|
| Myoblasts | 1 | 2003 | 234 | 0.050 |
Why?
|
| Histones | 1 | 2023 | 2591 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2023 | 265 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3233 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2007 | 704 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 5531 | 0.050 |
Why?
|
| Bronchi | 1 | 2006 | 847 | 0.050 |
Why?
|
| Intellectual Property | 1 | 2022 | 32 | 0.050 |
Why?
|
| Fertilization | 1 | 1983 | 197 | 0.050 |
Why?
|
| Glycolysis | 2 | 2003 | 837 | 0.050 |
Why?
|
| Mandatory Testing | 1 | 2002 | 23 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 3602 | 0.050 |
Why?
|
| Biological Factors | 1 | 2023 | 155 | 0.050 |
Why?
|
| Protein Interaction Mapping | 1 | 2006 | 619 | 0.050 |
Why?
|
| Pilot Projects | 4 | 2017 | 8724 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 9237 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 3424 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 1801 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2015 | 2818 | 0.050 |
Why?
|
| Homeostasis | 3 | 2011 | 3338 | 0.050 |
Why?
|
| Disease | 1 | 2007 | 674 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2013 | 2190 | 0.050 |
Why?
|
| Third-Party Consent | 1 | 2002 | 66 | 0.050 |
Why?
|
| Binding Sites | 5 | 2011 | 6001 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2006 | 644 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIbeta Subunit | 1 | 2021 | 2 | 0.050 |
Why?
|
| Antitubercular Agents | 2 | 2021 | 1380 | 0.050 |
Why?
|
| Sphingolipids | 1 | 2023 | 177 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 160 | 0.050 |
Why?
|
| Sulfurtransferases | 1 | 2021 | 17 | 0.050 |
Why?
|
| Dehydration | 1 | 2003 | 215 | 0.050 |
Why?
|
| Histidine | 1 | 2022 | 301 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2023 | 415 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2001 | 200 | 0.050 |
Why?
|
| Physical Education and Training | 1 | 2021 | 102 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 421 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1407 | 0.050 |
Why?
|
| Dextroamphetamine | 1 | 2021 | 132 | 0.050 |
Why?
|
| Aldosterone | 1 | 2006 | 881 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2003 | 502 | 0.050 |
Why?
|
| Diffusion of Innovation | 2 | 2014 | 723 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2006 | 1186 | 0.050 |
Why?
|
| Amphetamines | 1 | 2021 | 142 | 0.040 |
Why?
|
| Pregnancy Tests | 1 | 2000 | 33 | 0.040 |
Why?
|
| Organ Specificity | 3 | 2012 | 1966 | 0.040 |
Why?
|
| Calibration | 1 | 2003 | 813 | 0.040 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 7843 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2024 | 65219 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 6506 | 0.040 |
Why?
|
| Exodeoxyribonucleases | 1 | 2001 | 191 | 0.040 |
Why?
|
| Melanoma | 1 | 2019 | 5695 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2013 | 4504 | 0.040 |
Why?
|
| Automation | 2 | 2019 | 585 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2021 | 111 | 0.040 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 701 | 0.040 |
Why?
|
| Culture Media | 1 | 2002 | 889 | 0.040 |
Why?
|
| Tremor | 1 | 2021 | 197 | 0.040 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2002 | 496 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 36548 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 13635 | 0.040 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2020 | 44 | 0.040 |
Why?
|
| Interinstitutional Relations | 2 | 2003 | 235 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 2 | 2011 | 419 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2005 | 572 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6059 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2015 | 4527 | 0.040 |
Why?
|
| Environment | 1 | 2006 | 1119 | 0.040 |
Why?
|
| Acid Ceramidase | 1 | 2019 | 21 | 0.040 |
Why?
|
| Life Change Events | 1 | 2015 | 956 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 5836 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2013 | 6409 | 0.040 |
Why?
|
| Markov Chains | 3 | 2011 | 971 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2016 | 1343 | 0.040 |
Why?
|
| Age Factors | 3 | 2019 | 18386 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 1996 | 0.040 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2020 | 114 | 0.040 |
Why?
|
| Practice Management, Medical | 1 | 2001 | 191 | 0.040 |
Why?
|
| Guidelines as Topic | 2 | 2012 | 1394 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2019 | 5946 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2009 | 5881 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 2877 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2006 | 2091 | 0.040 |
Why?
|
| Genetic Techniques | 1 | 2002 | 429 | 0.040 |
Why?
|
| Psychiatry | 1 | 2011 | 1715 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2002 | 792 | 0.040 |
Why?
|
| Herpes Zoster | 1 | 2021 | 252 | 0.040 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2019 | 64 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2024 | 1563 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2013 | 2502 | 0.040 |
Why?
|
| Genome, Fungal | 1 | 2000 | 203 | 0.040 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 1999 | 102 | 0.040 |
Why?
|
| Intensive Care, Neonatal | 1 | 2000 | 201 | 0.040 |
Why?
|
| Psychopharmacology | 1 | 2000 | 146 | 0.040 |
Why?
|
| Jaundice, Neonatal | 1 | 1999 | 70 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 3212 | 0.040 |
Why?
|
| Micrognathism | 1 | 2018 | 64 | 0.040 |
Why?
|
| Reminder Systems | 1 | 2002 | 388 | 0.040 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2019 | 85 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 1983 | 877 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6208 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2013 | 4277 | 0.040 |
Why?
|
| Telephone | 1 | 2002 | 627 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2004 | 1155 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 2795 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2014 | 4857 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 3273 | 0.040 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2019 | 172 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2023 | 545 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2013 | 6279 | 0.040 |
Why?
|
| Lead Poisoning | 1 | 2000 | 318 | 0.040 |
Why?
|
| Private Sector | 1 | 2021 | 396 | 0.040 |
Why?
|
| Computer User Training | 1 | 1997 | 19 | 0.040 |
Why?
|
| Uterine Neoplasms | 1 | 2006 | 1425 | 0.040 |
Why?
|
| Cities | 1 | 2020 | 542 | 0.040 |
Why?
|
| Hand Deformities, Congenital | 1 | 2018 | 175 | 0.040 |
Why?
|
| Erythrocytes | 2 | 2018 | 2394 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1980 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2019 | 392 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2021 | 658 | 0.040 |
Why?
|
| Microcomputers | 2 | 1995 | 139 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2009 | 1937 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2001 | 1457 | 0.040 |
Why?
|
| Mammals | 1 | 2023 | 1126 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 2001 | 901 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 15647 | 0.040 |
Why?
|
| Prediabetic State | 1 | 2003 | 547 | 0.040 |
Why?
|
| Disease Progression | 4 | 2019 | 13616 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2012 | 1419 | 0.030 |
Why?
|
| India | 1 | 2004 | 2334 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2006 | 3684 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 2411 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2000 | 366 | 0.030 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 284 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2007 | 2031 | 0.030 |
Why?
|
| Lithium | 1 | 2020 | 599 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1852 | 0.030 |
Why?
|
| Trans-Activators | 2 | 2003 | 2849 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2011 | 6421 | 0.030 |
Why?
|
| Denmark | 1 | 2019 | 774 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 1 | 2019 | 880 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 348 | 0.030 |
Why?
|
| Acanthosis Nigricans | 1 | 1996 | 47 | 0.030 |
Why?
|
| Potassium Channels | 1 | 2019 | 534 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4408 | 0.030 |
Why?
|
| Exons | 2 | 2015 | 2393 | 0.030 |
Why?
|
| Gene Library | 2 | 2012 | 1066 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 2019 | 335 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2019 | 412 | 0.030 |
Why?
|
| Hirsutism | 1 | 1996 | 66 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 455 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2020 | 934 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2021 | 934 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1739 | 0.030 |
Why?
|
| Leukemia | 2 | 2002 | 1522 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 6544 | 0.030 |
Why?
|
| Health Planning Councils | 1 | 2015 | 11 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 2188 | 0.030 |
Why?
|
| Hospitals | 2 | 2021 | 3887 | 0.030 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2020 | 503 | 0.030 |
Why?
|
| California | 1 | 2019 | 1435 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2002 | 856 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 3432 | 0.030 |
Why?
|
| Blood Gas Analysis | 1 | 1996 | 382 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1999 | 1138 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2006 | 1542 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2011 | 3073 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2022 | 1065 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2020 | 811 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2000 | 1666 | 0.030 |
Why?
|
| Appendicitis | 1 | 2021 | 680 | 0.030 |
Why?
|
| Language | 1 | 2024 | 1550 | 0.030 |
Why?
|
| Health Care Costs | 2 | 2018 | 3243 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2019 | 1365 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 2017 | 498 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2019 | 760 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2019 | 902 | 0.030 |
Why?
|
| Nortriptyline | 1 | 2014 | 79 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 1996 | 426 | 0.030 |
Why?
|
| Canada | 1 | 2020 | 2120 | 0.030 |
Why?
|
| Spine | 1 | 2021 | 1132 | 0.030 |
Why?
|
| Amitriptyline | 1 | 2014 | 110 | 0.030 |
Why?
|
| Mice, Knockout | 3 | 2019 | 14456 | 0.030 |
Why?
|
| Body Mass Index | 3 | 2017 | 13046 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 586 | 0.030 |
Why?
|
| Neck | 1 | 2018 | 735 | 0.030 |
Why?
|
| Rectal Fistula | 1 | 2014 | 76 | 0.030 |
Why?
|
| Chromatin | 1 | 2006 | 2981 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 3247 | 0.030 |
Why?
|
| Social Security | 1 | 1994 | 103 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 1979 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2019 | 1338 | 0.030 |
Why?
|
| Genome, Bacterial | 1 | 2019 | 796 | 0.030 |
Why?
|
| Fuzzy Logic | 1 | 1994 | 58 | 0.030 |
Why?
|
| Triage | 1 | 2021 | 994 | 0.030 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2013 | 22 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2023 | 3635 | 0.030 |
Why?
|
| Neoplasm Metastasis | 3 | 2012 | 4887 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 1999 | 1238 | 0.030 |
Why?
|
| Insurance Claim Reporting | 1 | 2014 | 166 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1995 | 712 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2007 | 3966 | 0.030 |
Why?
|
| Patient Admission | 1 | 2021 | 1365 | 0.030 |
Why?
|
| Cell Survival | 3 | 2009 | 5747 | 0.030 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2014 | 104 | 0.030 |
Why?
|
| Organizations | 1 | 2014 | 172 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 11094 | 0.030 |
Why?
|
| England | 1 | 2014 | 533 | 0.030 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 3928 | 0.030 |
Why?
|
| Medical Audit | 1 | 2014 | 454 | 0.030 |
Why?
|
| Heart | 1 | 2006 | 4419 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 1607 | 0.030 |
Why?
|
| Respiration | 1 | 1999 | 1653 | 0.030 |
Why?
|
| Pulse | 1 | 1993 | 217 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2012 | 41 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 1384 | 0.030 |
Why?
|
| Kv1.1 Potassium Channel | 1 | 2012 | 29 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2019 | 3140 | 0.030 |
Why?
|
| Thyroiditis | 1 | 2013 | 85 | 0.030 |
Why?
|
| Face | 1 | 2018 | 1029 | 0.030 |
Why?
|
| Program Development | 1 | 2019 | 1297 | 0.030 |
Why?
|
| Financing, Organized | 1 | 2014 | 202 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 1971 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 1999 | 858 | 0.030 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2012 | 120 | 0.030 |
Why?
|
| Schools | 1 | 2021 | 1495 | 0.020 |
Why?
|
| Computers | 2 | 2005 | 588 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2004 | 1546 | 0.020 |
Why?
|
| Alzheimer Disease | 2 | 2011 | 8724 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 897 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2007 | 3682 | 0.020 |
Why?
|
| Fornix, Brain | 1 | 2012 | 71 | 0.020 |
Why?
|
| Models, Animal | 1 | 2018 | 2120 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2019 | 1064 | 0.020 |
Why?
|
| Amniotic Fluid | 1 | 1994 | 381 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2013 | 200 | 0.020 |
Why?
|
| Birth Weight | 1 | 2020 | 2122 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 663 | 0.020 |
Why?
|
| Cyclin A | 1 | 2011 | 59 | 0.020 |
Why?
|
| Inservice Training | 1 | 2014 | 375 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2013 | 404 | 0.020 |
Why?
|
| Citalopram | 1 | 2014 | 402 | 0.020 |
Why?
|
| Length of Stay | 2 | 2015 | 6490 | 0.020 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1995 | 419 | 0.020 |
Why?
|
| Iodide Peroxidase | 1 | 2013 | 295 | 0.020 |
Why?
|
| Computer Storage Devices | 1 | 1991 | 9 | 0.020 |
Why?
|
| Spleen | 1 | 2017 | 2294 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2021 | 1949 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2019 | 1218 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1997 | 1872 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 1988 | 0.020 |
Why?
|
| Sample Size | 1 | 2014 | 843 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2012 | 266 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2014 | 520 | 0.020 |
Why?
|
| Cyclin E | 1 | 2011 | 155 | 0.020 |
Why?
|
| Biostatistics | 1 | 2012 | 162 | 0.020 |
Why?
|
| Receptors, AMPA | 1 | 2012 | 335 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2018 | 2426 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2015 | 823 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 390 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 295 | 0.020 |
Why?
|
| Certification | 1 | 2014 | 420 | 0.020 |
Why?
|
| Mathematics | 2 | 2001 | 696 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 1996 | 352 | 0.020 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 498 | 0.020 |
Why?
|
| Gene Frequency | 2 | 2011 | 3623 | 0.020 |
Why?
|
| Reference Values | 3 | 2006 | 4909 | 0.020 |
Why?
|
| Adenosine Deaminase | 1 | 2012 | 253 | 0.020 |
Why?
|
| Educational Status | 1 | 1998 | 2510 | 0.020 |
Why?
|
| Positive-Pressure Respiration | 1 | 1995 | 712 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2004 | 5919 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 1882 | 0.020 |
Why?
|
| Cell Separation | 2 | 2006 | 1718 | 0.020 |
Why?
|
| Nylons | 1 | 2009 | 47 | 0.020 |
Why?
|
| Cell Death | 1 | 2015 | 1676 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 10380 | 0.020 |
Why?
|
| Homozygote | 1 | 2014 | 1774 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 998 | 0.020 |
Why?
|
| Breast Neoplasms | 5 | 2012 | 21074 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2014 | 584 | 0.020 |
Why?
|
| Alpinia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 1996 | 1021 | 0.020 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2009 | 142 | 0.020 |
Why?
|
| Income | 1 | 1998 | 1874 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 2969 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 2395 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 1885 | 0.020 |
Why?
|
| Recurrence | 1 | 2021 | 8494 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 1893 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2009 | 169 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 2006 | 3089 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2012 | 673 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 945 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 829 | 0.020 |
Why?
|
| Anisotropy | 1 | 2012 | 1284 | 0.020 |
Why?
|
| Methotrexate | 1 | 2015 | 1719 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 622 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2021 | 3586 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 5758 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2009 | 1167 | 0.020 |
Why?
|
| Glycoproteins | 2 | 2006 | 2196 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 17597 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 1716 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2018 | 2464 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 889 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 11035 | 0.020 |
Why?
|
| Brain Stem Neoplasms | 1 | 2009 | 192 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 5739 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 514 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 14747 | 0.020 |
Why?
|
| Colectomy | 1 | 2012 | 697 | 0.020 |
Why?
|
| Hemopexin | 1 | 2006 | 33 | 0.020 |
Why?
|
| Protein Stability | 1 | 2008 | 576 | 0.020 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2006 | 54 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2006 | 74 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 1805 | 0.020 |
Why?
|
| RNA Interference | 1 | 2015 | 2828 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 951 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2006 | 97 | 0.020 |
Why?
|
| Hypertension | 2 | 2005 | 8616 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2006 | 163 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 2413 | 0.020 |
Why?
|
| Genes, cdc | 1 | 2006 | 113 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2010 | 9540 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2010 | 661 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6309 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 380 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2006 | 82 | 0.020 |
Why?
|
| Pain | 1 | 2021 | 5090 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 3344 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 2271 | 0.020 |
Why?
|
| Synteny | 1 | 2005 | 76 | 0.020 |
Why?
|
| Gyrus Cinguli | 1 | 2012 | 1118 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2012 | 1531 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2009 | 1085 | 0.020 |
Why?
|
| Mice, Inbred mdx | 1 | 2005 | 90 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1996 | 4188 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3818 | 0.020 |
Why?
|
| Health Behavior | 1 | 2017 | 2649 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2015 | 2630 | 0.020 |
Why?
|
| Bronchoconstriction | 1 | 2006 | 141 | 0.020 |
Why?
|
| Erythroid Precursor Cells | 1 | 2006 | 211 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2017 | 3315 | 0.020 |
Why?
|
| Caregivers | 1 | 1998 | 2304 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 1995 | 2171 | 0.020 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2007 | 216 | 0.020 |
Why?
|
| Breast | 2 | 2004 | 1950 | 0.020 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2006 | 323 | 0.020 |
Why?
|
| Maps as Topic | 1 | 2005 | 18 | 0.020 |
Why?
|
| Haptoglobins | 1 | 2006 | 165 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2006 | 279 | 0.020 |
Why?
|
| Fibroblast Growth Factor 9 | 1 | 2004 | 13 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 1305 | 0.010 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2004 | 43 | 0.010 |
Why?
|
| Receptors, Neuropeptide | 1 | 2005 | 106 | 0.010 |
Why?
|
| Receptor, PAR-2 | 1 | 2004 | 33 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 398 | 0.010 |
Why?
|
| Gestational Age | 2 | 2009 | 3616 | 0.010 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 225 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 473 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2004 | 81 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 478 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 462 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 2004 | 135 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2004 | 325 | 0.010 |
Why?
|
| Genes, jun | 1 | 2003 | 69 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 420 | 0.010 |
Why?
|
| Disease Models, Animal | 3 | 2009 | 18321 | 0.010 |
Why?
|
| Child Development | 1 | 1995 | 2327 | 0.010 |
Why?
|
| Nuclear Respiratory Factors | 1 | 2003 | 17 | 0.010 |
Why?
|
| Myositis, Inclusion Body | 1 | 2005 | 145 | 0.010 |
Why?
|
| NF-E2-Related Factor 1 | 1 | 2003 | 21 | 0.010 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2003 | 23 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7474 | 0.010 |
Why?
|
| National Health Programs | 1 | 2007 | 444 | 0.010 |
Why?
|
| Genes, fos | 1 | 2003 | 176 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 1883 | 0.010 |
Why?
|
| Astrocytes | 1 | 2011 | 1353 | 0.010 |
Why?
|
| Interferon-beta | 1 | 2005 | 347 | 0.010 |
Why?
|
| Cell Cycle Proteins | 2 | 2005 | 3436 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 12976 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2003 | 515 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2019 | 4746 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1999 | 8532 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 322 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 2004 | 373 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 636 | 0.010 |
Why?
|
| Critical Care | 1 | 1995 | 2714 | 0.010 |
Why?
|
| Cell Movement | 1 | 2015 | 5196 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 2003 | 320 | 0.010 |
Why?
|
| Laminin | 1 | 2004 | 404 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 327 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10737 | 0.010 |
Why?
|
| Oximetry | 2 | 1997 | 461 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2004 | 343 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2006 | 576 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2006 | 992 | 0.010 |
Why?
|
| Iris Plant | 1 | 2002 | 1 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 2627 | 0.010 |
Why?
|
| Ribosomes | 1 | 2005 | 495 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2003 | 275 | 0.010 |
Why?
|
| Mexican Americans | 1 | 2003 | 165 | 0.010 |
Why?
|
| Bone Development | 1 | 2005 | 468 | 0.010 |
Why?
|
| Dermatomyositis | 1 | 2005 | 261 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 613 | 0.010 |
Why?
|
| Citric Acid Cycle | 1 | 2003 | 228 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 595 | 0.010 |
Why?
|
| Muscle Development | 1 | 2003 | 258 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 1241 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 697 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 444 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2004 | 561 | 0.010 |
Why?
|
| Molecular Probes | 1 | 2003 | 309 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2005 | 909 | 0.010 |
Why?
|
| Meiosis | 1 | 1983 | 326 | 0.010 |
Why?
|
| Tears | 1 | 2003 | 254 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 794 | 0.010 |
Why?
|
| Neurodegenerative Diseases | 1 | 2010 | 1088 | 0.010 |
Why?
|
| Dogs | 1 | 2005 | 3824 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 931 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2006 | 1164 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2006 | 3584 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2008 | 1263 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2011 | 2778 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 1242 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 1131 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 2469 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 12827 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 4054 | 0.010 |
Why?
|
| Fetus | 1 | 2006 | 1878 | 0.010 |
Why?
|
| Troponin T | 1 | 2004 | 785 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 1825 | 0.010 |
Why?
|
| Muscles | 1 | 2003 | 1576 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 853 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2003 | 1820 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2003 | 734 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2014 | 4859 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 2144 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 2076 | 0.010 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 6363 | 0.010 |
Why?
|
| Hedgehog Proteins | 1 | 2002 | 771 | 0.010 |
Why?
|
| Liability, Legal | 1 | 1998 | 209 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 2815 | 0.010 |
Why?
|
| Physical Examination | 1 | 2003 | 1263 | 0.010 |
Why?
|
| Mental Recall | 1 | 2003 | 1217 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 4466 | 0.010 |
Why?
|
| Antioxidants | 1 | 2004 | 1671 | 0.010 |
Why?
|
| Collagen | 1 | 2004 | 2617 | 0.010 |
Why?
|
| Neuronal Plasticity | 1 | 2004 | 1447 | 0.010 |
Why?
|
| Nurses | 1 | 2005 | 2503 | 0.010 |
Why?
|
| Patient Advocacy | 1 | 1997 | 361 | 0.010 |
Why?
|
| Learning | 1 | 2004 | 1755 | 0.010 |
Why?
|
| Social Responsibility | 1 | 1997 | 382 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 3227 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2006 | 3050 | 0.010 |
Why?
|
| Regeneration | 1 | 2002 | 1516 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 9354 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2005 | 3209 | 0.010 |
Why?
|
| Protein Binding | 1 | 2005 | 9301 | 0.010 |
Why?
|
| Insulin | 1 | 2007 | 6604 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1994 | 403 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2004 | 3955 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1994 | 587 | 0.010 |
Why?
|
| Social Class | 1 | 2000 | 2007 | 0.010 |
Why?
|
| Calcium | 1 | 2004 | 5770 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1994 | 518 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 10260 | 0.000 |
Why?
|
| Patient Satisfaction | 1 | 1995 | 3477 | 0.000 |
Why?
|